European Archives - Page 1341 of 1425 - European Medical Journal

EMJ

ECC 2015: New survival data from Combi-v trial of combination of two targeted therapies in melanoma

Updated results from the phase 3 COMBI-v trial of a combination of dabrafenib and trametinib for the first-line treatment of patients with…

EMJ

ECC 2015: NETTER-1 trial showed rare cancer responded unusually well to new treatment

NETTER-1, a phase 3 clinical trial, evaluated Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in patients with Grade 1–2 metastatic…

EMJ

ECC 2015: RADIANT-4 trial showed promise in the treatment of neuroendocrine tumours

RADIANT-4, a placebo-controlled, double-blind, phase 3 clinical trial conducted in centres in 13 European countries, Korea, Japan, Canada, and the US…

EMJ

ECC 2015: Launch of the European Society for Paediatric Oncology (SIOPE) strategic plan

The European Society for Paediatric Oncology (SIOP Europe or SIOPE), is a pan-European organisation that represents professionals working in the field…

EMJ

ECC 2015: News briefing chaired by Prof Martine Piccart

At the European Cancer Congress (ECC) 2015, Martine Piccart, MD, PhD, of Université Libre de Bruxelles and Institut Jules Bordet, Brussels, Belgium…

EMJ

ECC 2015: CheckMate 025 trial showed nivolumab improved overall survival in advanced kidney cancer

CheckMate 025, a phase 3 clinical trial, compared the anti-programmed cell death protein-1 (PD-1) antibody, nivolumab, with the standard treatment…

EMJ

ECC 2015: EUROCARE-5 trial showed large variations in blood cancer survival in Europe

Comparisons of cancer patients’ survival and care in Europe up to 2007 showed that although more patients are surviving for at least five years after…

EMJ

ECC 2015: METEOR trial showed cabozantinib improved survival in advanced kidney cancer

METEOR, a phase 3 clinical trial, compared cabozantinib with everolimus for the treatment of patients with advanced clear cell renal cell carcinoma.

EMJ

The value of an intermediate Recurrence Score® result in the Oncotype DX® Breast Cancer Assay

The Oncotype DX® Breast Cancer Assay is a 21-gene assay that provides a Recurrence Score® (RS), which is divided into low-, intermediate- and high-risk…

EMJ

TERRAIN trial of enzalutamide versus bicalutamide for advanced prostate cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC…